cemiplimab-rwlc
Showing 1 - 5 of 5
Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck Trial in Tucson, Tampa
Terminated
- Cutaneous Squamous Cell Carcinoma
- Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Cemiplimab-Rwlc
-
Tucson, Arizona
- +1 more
Nov 2, 2022
Head and Neck Squamous Cell Carcinoma, HNSCC, Squamous Cell Carcinoma of the Larynx Trial (Cemiplimab-Rwlc)
Withdrawn
- Head and Neck Squamous Cell Carcinoma
- +4 more
- Cemiplimab-Rwlc
- (no location specified)
Aug 1, 2022
Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Advanced Squamous Cell Carcinoma Trial in Miami (Cemiplimab-Rwlc,
Not yet recruiting
- Cutaneous Squamous Cell Carcinoma
- +2 more
- Cemiplimab-Rwlc
- PEG-IFN alfa-2a
-
Miami, FloridaMiami Cancer Institute at Baptist Health, Inc.
Feb 6, 2023
Glioblastoma Trial in United States (Ad-RTS-hIL-12, Veledimex, Cemiplimab-Rwlc)
Completed
- Glioblastoma
- Ad-RTS-hIL-12
- +2 more
-
Los Angeles, California
- +6 more
Nov 3, 2021
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Metastatic Cancer Trial in United States (CMP-001, cemiplimab-rwlc)
Recruiting
- Merkel Cell Carcinoma
- +4 more
- CMP-001
- cemiplimab-rwlc
-
Jacksonville, Florida
- +6 more
Feb 24, 2022